JD Health International (SEHK:6618) Could Be 43% Undervalued As Half Year Profit Rises

Simply Wall St.08-24

AdvertisementWhy JD Health International’s Latest Earnings Matter For Investors JD Health International (SEHK:6618) drew fresh attention after reporting half year 2026 earnings, with higher sales, net...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2661224557?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/4422000-choice1-main-header/1585186589176","is_english":true,"pubTime":"2026-08-24 01:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2661224557","market":"us","top_or_hot":-1,"title":"JD Health International (SEHK:6618) Could Be 43% Undervalued As Half Year Profit Rises","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy JD Health International’s Latest Earnings Matter For Investors JD Health International (SEHK:6618) drew fresh attention after reporting half year 2026 earnings, with higher sales, net...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/jd-health-international-sehk6618-could-be-43-undervalued-as\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JD Health International (SEHK:6618) Could Be 43% Undervalued As Half Year Profit Rises</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJD Health International (SEHK:6618) Could Be 43% Undervalued As Half Year Profit Rises\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-24 01:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/jd-health-international-sehk6618-could-be-43-undervalued-as><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy JD Health International’s Latest Earnings Matter For Investors JD Health International (SEHK:6618) drew fresh attention after reporting half year 2026 earnings, with higher sales, net...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/jd-health-international-sehk6618-could-be-43-undervalued-as\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1571","symbol_name":"互联网医疗","start_time":0,"source_url":"https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/jd-health-international-sehk6618-could-be-43-undervalued-as","article_id":"2661224557","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/4422000-choice1-main-header/1585186589176"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/jd-health-international-sehk6618-could-be-43-undervalued-as","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2661224557","pubTimestamp":1787505428,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why JD Health International’s Latest Earnings Matter For Investors\nJD Health International (SEHK:6618) drew fresh attention after reporting half year 2026 earnings, with higher sales, net income and earnings per share compared with the same period a year earlier.\nSee our latest analysis for JD Health International.\nDespite the stronger half year earnings, JD Health International’s share price tells a mixed story. The stock is at HK$38.66 after a 1 day share price return of 1.63%, yet the year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"86618":"京东健康-R","BK1571":"互联网医疗","BK1589":"北水核心资产","SGXZ62798434.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) ACC","BK1515":"抗疫概念","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","BK1247":"药品零售","BK1142":"互联网与直销零售","06618":"京东健康","BK1591":"就地过年概念","BK1615":"港股-互联网","LU0051755006.USD":"摩根大通中国A (dist)","SGXZ86797644.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) INC","BK1583":"高瓴概念"},"translate_title":"京东健康国际（SEHK:6618）半年利润增长可能被低估 43%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"86618":0.6,"06618":1.98},"content_text":"AdvertisementWhy JD Health International’s Latest Earnings Matter For Investors JD Health International (SEHK:6618) drew fresh attention after reporting half year 2026 earnings, with higher sales, net income and earnings per share compared with the same period a year earlier. See our latest analysis for JD Health International. Despite the stronger half year earnings, JD Health International’s share price tells a mixed story. The stock is at HK$38.66 after a 1 day share price return of 1.63%, yet the year to date share price return is down 31.39% and the 1 year total shareholder return is down 39.12%. This suggests that recent momentum is still weak compared with earlier years. If you are reassessing your exposure to digital healthcare after JD Health International’s results, this can be a moment to look at other opportunities in the sector through 129 healthcare AI stocks. Given JD Health International’s solid half year figures but weak longer term share returns, you need to judge whether the stock is now pricing in business progress or mostly reflecting cautious sentiment. The valuation metrics give the next clues. Most Popular Narrative: 43.3% Undervalued At a last close of HK$38.66 versus a narrative fair value of HK$68.17, JD Health International is framed as materially undervalued, with that gap anchored to long term earnings and margin expectations using a 7.18% discount rate.  Rapid acceleration in AI integration across medical consultations, diagnostics, and service delivery is driving higher operational efficiency, elevated user satisfaction, and improved conversion rates, supporting upward momentum in both revenue and net margins.  Read the complete narrative. Want to see what kind of revenue path and margin profile would justify that higher fair value for JD Health International? The narrative leans on steady top line expansion, a specific earnings target and a richer future earnings multiple that assumes the platform’s scale really pays off. Result: Fair Value of HK$68.17 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, analysts also flag rising competition in Chinese digital healthcare and potential regulatory shifts around medical insurance payments that could limit JD Health International’s earnings power. Find out about the key risks to this JD Health International narrative. Another View On JD Health International’s Valuation The narrative fair value frames JD Health International as 43.3% undervalued at HK$68.17, yet the P/E picture is more nuanced. The stock trades on 17x earnings, above the Asian Consumer Retailing industry at 15.7x, but below a fair ratio of 21x that the market could move toward. That mix of relative expensiveness to the sector and discount to the fair ratio raises a simple question: Is the current price compensating you enough for the business risks and execution hurdles ahead? See what the numbers say about this price — find out in our valuation breakdown. SEHK:6618 P/E Ratio as at Aug 2026Next Steps After weighing JD Health International’s recent earnings and valuation signals, it makes sense to pressure test the optimism and risks against your own expectations. To see what the market currently views as the key upside drivers, take a closer look at the 3 key rewards. Looking for more investment ideas beyond JD Health International? If JD Health International’s story has you rethinking your portfolio, this is a good moment to broaden your watchlist using focused stock ideas from the Simply Wall St screener.  Spot underappreciated quality by reviewing companies flagged as 267 high quality undervalued stocks that might offer a more attractive entry point than the broader market. Strengthen your income stream through stocks in the 424 dividend fortresses that aim to combine higher yields with resilience. Prioritise resilience first by checking companies in the 291 resilient stocks with low risk scores that score well on stability and downside protection.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2661224557","isCrawlerRequest":true}